HIV vaccines: Can CD4+ T cells be of help?

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 12, 2012, Pages 1795-1798

  Van Braeckel, Eva ^a   Leroux Roels, Geert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

CD4 T cells; Experimental vaccines; HIV; HIV vaccine; T helper cells

Indexed keywords

GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; NEF PROTEIN; PROTEIN P17; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; NONHUMAN; NOTE; T LYMPHOCYTE ACTIVATION; VACCINATION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS LOAD; VIRUS NEUTRALIZATION;

CD4 T-CELLS; EXPERIMENTAL VACCINES; HIV; HIV VACCINE; T HELPER CELLS;

AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE TRANSMISSION, INFECTIOUS; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 84872234479     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.21760     Document Type: Note

References (40)

1. Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220:865-7; PMID:6601823; http://dx.doi.org/10.1126/science.6601823.
2. Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220:868-71; PMID:6189183; http://dx.doi.org/10.1126/science.6189183.
3. WHO. HIV/AIDS. Fact sheet No 360: World Health Organization, 2012.
4. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-65; PMID:15688278; http://dx.doi.org/10.1086/428404.
5. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M, et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005; 191:666-77; PMID:15688279; http://dx.doi.org/10.1086/428405.
6. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al.; Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93; PMID:19012954; http://dx.doi.org/10.1016/S0140-6736(08)61591-3.
7. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al.; Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905; PMID:19012957; http://dx.doi.org/10.1016/S0140-6736(08)61592-5.
8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.; MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492.
9. McMichael AJ, Haynes BF. Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nat Immunol 2012; 13:423-7; PMID:22513323; http://dx.doi.org/10.1038/ni.2264.
10. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol 2008; 82:12449-63; PMID:18842730; http://dx.doi.org/10.1128/JVI.01708-08.
11. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-9; PMID:12644702; http://dx.doi.org/10.1073/pnas.0630530100.
12. Stamatatos L, Morris L, Burton DR, Mascola JR. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009; 15:866-70; PMID:19525964.
13. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, et al.; The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340-8; PMID:8568294; http://dx.doi.org/10.1093/infdis/173.2.340.
14. Roehr B. Researchers announce first correlates of protection for HIV vaccine. BMJ (Clinical research ed 2011; 343:d5880.
15. Cohen J. AIDS research. Novel antibody response may explain HIV vaccine success. Science 2011; 333:1560; PMID:21921167; http://dx.doi.org/10.1126/ science.333.6049.1560.
16. McDermott AB, Koup RA. CD8(+) T cells in preventing HIV infection and disease. AIDS 2012; 26:1281-92; PMID:22441256; http://dx.doi.org/10.1097/QAD. 0b013e328353bcaf.
17. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 2009; 106:19940-5; PMID:19918060.
18. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009; 457:87-91; PMID:18997770; http://dx.doi.org/10.1038/nature07469.
19. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464:224-31; PMID:20220841; http://dx.doi.org/10.1038/nature08898.
20. Day CL, Walker BD. Progress in defining CD4 helper cell responses in chronic viral infections. J Exp Med 2003; 198:1773-7; PMID:14676292; http://dx.doi.org/10.1084/jem.20031947.
21. Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200:701- 12; PMID:15381726; http://dx.doi.org/10.1084/jem.20041270.
22. Girard MP, Osmanov S, Assossou OM, Kieny MP. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011; 29:6191-218; PMID:21718747; http://dx.doi.org/10.1016/j.vaccine.2011.06.085.
23. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M; ESN Study Group. The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009; 23:161-75; PMID:19098485; http://dx.doi.org/10.1097/QAD. 0b013e3283196a80.
24. Alimonti JB, Koesters SA, Kimani J, Matu L, Wachihi C, Plummer FA, et al. CD4+ T cell responses in HIV-exposed seronegative women are qualitatively distinct from those in HIV-infected women. J Infect Dis 2005; 191:20-4; PMID:15592998; http://dx.doi.org/10.1086/425998.
25. Kebba A, Kaleebu P, Serwanga J, Rowland S, Yirrell D, Downing R, et al. HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans. AIDS Res Hum Retroviruses 2004; 20:67-75; PMID:15000700; http://dx.doi.org/10.1089/088922204322749512.
26. Ritchie AJ, Campion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, et al. Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. J Virol 2011; 85:3507-16; PMID:21270166; http://dx.doi.org/10.1128/JVI.02444-10.
27. Boaz MJ, Waters A, Murad S, Easterbrook PJ, Vyakarnam A. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002; 169:6376-85; PMID:12444145.
28. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169-78; PMID:16254352; http://dx.doi.org/10.1128/JVI.79.22.14169-14178.2005.
29. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 2007; 81:12071-6; PMID:17728221; http://dx.doi.org/10.1128/JVI.01261-07.
30. Imami N, Pires A, Hardy G, Wilson J, Gazzard B, Gotch F. A balanced type 1/type 2 response is associated with long-term nonprogressive human immunodeficiency virus type 1 infection. J Virol 2002; 76:9011-23; PMID:12186885; http://dx.doi.org/10.1128/JVI.76.18.9011-9023.2002.
31. Gloster SE, Newton P, Cornforth D, Lifson JD, Williams I, Shaw GM, et al. Association of strong virus-specific CD4 T cell responses with efficient natural control of primary HIV-1 infection. AIDS 2004; 18:749-55; PMID:15075509; http://dx.doi.org/10.1097/00002030-200403260-00005.
32. Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis 2007; 195:546-50; PMID:17230414; http://dx.doi.org/10.1086/ 510909.
33. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med 2007; 356:2073-81; PMID:17507706; http://dx.doi.org/10.1056/NEJMra066267.
34. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95-8; PMID:11986671; http://dx.doi.org/10.1038/417095a.
35. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:518-25; PMID:10229228; http://dx.doi.org/10.1038/8400.
36. Pike R, Filby A, Ploquin MJ, Eksmond U, Marques R, Antunes I, et al. Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection. J Virol 2009; 83:11211-22; PMID:19692462; http://dx.doi.org/10.1128/JVI.01225-09.
37. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217-23; PMID:20220840; http://dx.doi.org/10.1038/ nature08757.
38. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-9; PMID:19219024; http://dx.doi.org/10.1038/nm.1935.
39. Leroux-Roels I, Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 2010; 28:7016-24; PMID:20728522; http://dx.doi.org/10.1016/j.vaccine.2010.08.035.
40. Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, et al. An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers. Clin Infect Dis 2011; 52:522-31; PMID:21208909; http://dx.doi.org/10.1093/cid/ ciq160.